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Abstract 
Purpose. The cannabinoid receptor CB2 is predominantly expressed in non-neuronal tissues 
and exerts potent immunmodulatory functions. The aim of the present study was to evaluate 
the role of CB2 in the pathogenesis of dermal fibrosis. 
Methods. Mice deficient for CB2 (CB2 -/-) and their wildtype littermates (CB2 +/+) were 
injected with bleomycin to induce experimental fibrosis. In addition, mice were treated with 
selective agonists and antagonists of CB2. Lesional skin was evaluated for dermal thickness 
and numbers of infiltrating leukocytes. Bone marrow transplantation experiments were 
performed. 
Results. CB2 -/- mice were more sensitive to bleomycin induced dermal fibrosis than CB2 +/+ 
mice with increased dermal thickness. Leukocytes counts were significantly higher in lesional 
skin of CB2 +/+ mice. Increased dermal fibrosis was also observed upon treatment with the 
CB2 antagonist AM-630. In contrast, the selective CB2 agonist JWH-133 reduced leukocyte 
infiltration and dermal thickening. The phenotype of CB2 -/- mice was mimicked by 
transplantation of CB2 -/- bone marrow into CB2 +/+ mice, whereas CB2 -/- mice transplanted 
with bone marrow from CB2 +/+ mice did not display an increased sensitivity to bleomycin 
induced fibrosis, indicating that leukocyte expression of CB2 is critically influencing 
experimental fibrosis. 
Conclusion. We demonstrate in the present study that CB2 limits leukocyte infiltration and 
tissue fibrosis in experimental dermal fibrosis. Since selective CB2 agonists are available and 
well tolerated, CB2 might be an interesting molecular target for the treatment of early 
inflammatory stages of SSc.  
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Introduction 
Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology that 
affects the skin and a variety of internal organs. In early stages, inflammatory infiltrates are a 
histopathological hallmark of SSc (1). The inflammatory infiltrates are dominated by 
monocytes and activated T cells. Later stages of the disease are characterized by an excessive 
accumulation of extracellular matrix components. The resulting fibrosis frequently leads to 
dysfunction of the affected organs, which is a major cause of death in SSc patients. The 
overproduction of extracellular matrix components in SSc patients is mediated by activated 
fibroblasts. The mechanisms leading to the activation of fibroblasts in SSc particular how 
leukocytes regulate this process are poorly understood so far (1). The observation that 
activated fibroblasts that release excessive amounts of collagen, are mainly localized adjacent 
to inflammatory infiltrates support concepts that leukocytes constitute to initiation of fibrosis 
in early stages of SSc (2). 
 In the early 1990s, two different receptors for the marijuana component Δ9-
tetrahydrocannabinol have been identified and were named CB1 and CB2 (3, 4). Both 
receptors are heterotrimeric GTP binding protein coupled receptors. CB1 is primarily 
expressed in the central nervous system, whereas CB2 is predominantly expressed in 
peripheral tissues. The ligands for CB1 and CB2, the so-called cannabinoids, can be 
subdivided into three different groups according to their origin. The family of cannabinoids 
includes plant derived cannabinoids, synthetic cannabinoids and endogenous cannabinoids 
(endocannabinoids) that are synthesized within the human body (5). Besides their effects in 
the CNS, endocannabinoids regulate physiological and pathophysiological processes in non-
neuronal tissues. Cannabinoids possess anti-tumor effects with inhibition of tumor cell 
proliferation and induction of cell cycle arrest in transformed cells. Endocannabinoids also 
orchestrate immune responses by regulating cytokine release, chemotaxis, proliferation and 
activation of leukocytes. Furthermore, cannabinoids play a central role for bone metabolism 
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and turn over as they control proliferation and activation of osteoblasts as well as 
differentiation of mononuclear precursor cells into osteoclasts (5, 6). Endocannabinoids might 
also play a role in fibrotic diseases. Recent data demonstrated that cannabinoids regulate the 
activation of hepatic stellate cells, which contribute to the pathogenesis of liver fibrosis (7). 
Stimulation of CB2 reduced the proliferation of hepatic stellate cells and reduced oxidative 
stress in preclinical models (7). Expression of CB2 has also been found in the skin suggesting 
that CB2 signaling might play a role in dermal fibrosis (8-10). 
 The broad implication of the endocannabinoid system into different diseases resulted 
in considerable interest from pharmaceutical companies and stimulated the development of a 
number of synthetic small molecules that target the CB2 receptor. Several of these 
compounds are currently evaluated in clinical trials, e.g. selective CB2 agonists for immune 
modulation in multiple sclerosis (6). First results from these trials indicate that a potent 
inhibition of the cannabinoid receptors can be achieved in humans and that the rate of severe 
adverse events of this class of drugs is low.     
 The aim of the present study was to investigate the role of the peripheral cannabinoid 
receptor CB2 in experimental dermal fibrosis. We demonstrate that inhibition of CB2 
signaling either by gene silencing or by small molecule inhibitors increases the susceptibility 
to fibrosis. Moreover, activation of CB2 signaling reduced leukocyte infiltration into lesional 
skin and prevented the development of experimental fibrosis. Thus, stimulation of CB2 might 
be an interesting anti-fibrotic approach in early inflammatory stages of SSc.  
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Material and methods 
Bleomycin-induced dermal fibrosis in CB2 deficient mice 
Mice deficient for CB2 (CB2 -/-) have been described previously (11). CB2 -/- mice 
were backcrossed onto a C57Bl/6 background for at least 6 generations. Matched wildtype 
C57Bl/6 mice expressing CB2 (CB2 +/+) from the same breedings were used as controls. Skin 
fibrosis was induced in 6-week-old mice by local injections of bleomycin for 4 weeks as 
described (12). Briefly, 100 μl of bleomycin dissolved in 0.9% sodium chloride (NaCl) at a 
concentration of 0.5 mg/ml were administered every other day by subcutaneous injections in 
defined areas of 1 cm2 at the upper back. Subcutaneous injections of 100 μl 0.9% NaCl were 
used as controls. Four different groups, consisting of two groups with CB2 -/- mice and CB2 
+/+ mice were analyzed. One group of CB2 -/- mice and one group of CB2 +/+ mice were 
challenged with bleomycin, whereas the remaining two groups were injected with NaCl. After 
4 weeks, animals were sacrificed by cervical dislocation. The four groups consisted of 8 mice 
each. All animal experiments were approved by the local ethical committee. 
 
Effects of CB2 antagonists and agonists on experimental fibrosis 
To confirm the increased susceptibility of CB2 -/- mice to fibrosis with a 
pharmacological approach, C57Bl/6 mice challenged with bleomycin were treated with 
selective CB2 agonists or antagonists, respectively. AM-630 (6-Iodo-2-methyl-1-[2-(4-
orpholinyl)ethyl]-1H-indol-3-yl](4-methoxy-phenyl)methanone) is a selective antagonists of 
CB2 with a Ki value of 31.2 nM. Other receptors including CB1 are not affected by AM630 in 
pharmacologically relevant concentrations. JWH-133 ((6aR,10aR)-3-(1,1-dimethylbutyl)-
6a,7,10,10a-tetrahydro-6,6,9-tri-methyl-6H-di-benzo[b,d] pyran) selectively activates CB2 
with a Ki value of 3.4 nM and a 200-fold selectivity over CB1. Both compounds were 
purchased from Biozol (Eching, Germany). AM-630 and JWH-133 were dissolved in DMSO 
at a concentration of 10 mg/ml. The working solutions were prepared fresh on the day of the 
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experiments by diluting the stock solutions in NaCl. Mice injected with equal volumes of the 
solvent were used for controls. Treatment with AM-630 and JWH-133 was started in parallel 
to bleomycin challenge. AM-630 and JWH-133 were administered by daily intraperitoneal 
injections at concentrations of 2.5 mg/kg/d in a total volume of 100 μl for 4 weeks. Each 
treatment group consisted of 6 mice. 
 
Bone marrow transplantation 
To investigate the relative contribution of fibroblasts and other mesenchymal cells and 
bone marrow derived cells to the phenotype of CB2 -/-, bone marrow transplantation 
experiments were performed. Female CB2 -/- and CB2 +/+ mice served as donors for bone 
marrow. For isolation of unfractioned bone marrow cells, tibial and femur bones were 
prepared under sterile conditions. Bone marrow cells were flushed from the bones marrow 
cavities with phosphate-buffered saline and subsequently filtered through 70 µm nylon 
mashes (BD Biosciences, Heidelberg, Germany). Erythrocytes were hemolyzed and the 
remaining bone marrow cells were kept on ice until the time of transplantation. All isolated 
bone marrow cells were transplanted together without further purification or in vitro 
expansion of a particular subset of cells. Male CB2 -/- or CB2 +/+ mice were transplanted at an 
age of 4 weeks. 16 h before transplantation, recipient CB2 -/- or CB2 +/+ mice underwent whole 
body irradiation with 11 Gy. For transplantation, 2.0 x 106 bone marrow cells of donor mice 
were resuspended in 0.2 ml PBS and injected via the tail veins. To exclude sublethal 
irradiation and reconstitution by the old bone marrow, CB2 -/- and CB2 +/+ mice were 
irradiated, but did not receive bone marrow transplants. Two weeks after bone marrow 
transplantation and after confirmation of a complete reconstitution of the hematopoiesis by 
the transplanted cells, mice were challenged with bleomycin for 4 weeks as described above. 
All groups of mice consisted of six animals each. 
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Histological analysis  
Lesional skin areas were excised, fixed in 4% formalin and embedded in paraffin. 5 
µm sections were stained with hematoxylin and eosin. The dermal thickness was analyzed at 
100-fold magnification by measuring the distance between the epidermal-dermal junction and 
the dermal-subcutaneous fat junction at three sites from lesional skin of each mouse (13). 
Collagen fibers were visualized by Masson´s trichrome staining (Sigma-Aldrich, Munich, 
Germany) according to the instructions of the manufacturer and analyzed at 1000-fold 
magnification. Infiltrating leukocytes in lesional skin of CB2 -/- mice, CB2 +/+ mice and CB2 
+/+ mice treated with AM-630 or JWH-133 were quantified on hematoxylin and eosin stained 
sections. 25 different high power fields from different tissue sites from each mouse were 
evaluated for polymononuclear cells at 200-fold magnification by an experienced examiner 
blinded to the treatment. Images were captured with a Nikon Eclipse 80i microscope 
(Badhoevedorp, Netherlands) equipped with a DSP 3CCD camera (Sony, Tokyo, Japan).  
   
Statistics 
Data are expressed as mean  standard error of the mean. The Mann-Whitney-U-test 
was used for statistical analyses. A p-value of less than 0.05 was considered statistically 
significant.  
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Results 
Increased sensitivity of CB2 -/- mice for bleomycin induced dermal fibrosis 
 To evaluate, whether CB2 plays a role for the development of dermal fibrosis, CB2 -/- 
mice and CB2 +/+ mice (wildtpye mice) were challenged with bleomycin. Skin architecture 
and dermal thickness did not differ between CB2 -/- mice and CB2 +/+ mice injected with 
NaCl, suggesting that the skin phenotype is not altered in CB2 -/- mice under non-fibrotic 
conditions (Figures 1 and 2). Upon injection of bleomycin, the dermal thickness increased in 
CB2 -/- and in CB2 +/+ mice (Figures 1 and 2). However, CB2 -/- mice were significantly more 
susceptible to the induction of fibrosis by bleomycin than CB2 +/+ mice. In CB2 -/- mice, the 
dermal thickness increased by 72 ± 6 % as compared to 45 ± 6 % in CB2 +/+ mice (p = 0.028) 
(Figure 2). These data suggest that CB2 -/- mice might be more susceptible to bleomycin 
induced fibrosis.  
 
Pharmacological modification of CB2 signaling affects the outcome of dermal fibrosis  
 To confirm our findings on CB2 -/- mice by a pharmacologic approach, CB2 +/+ mice 
were treated with AM-630, a specific inhibitor of CB2. Treatment of mice with AM-630 
during bleomycin challenge lead to a significantly more pronounced increase in dermal 
thickness than injection with bleomycin alone (128 ± 8 % vs. 68 ± 3 %, p = 0.004) (Figures 3 
and 4). Thus, inhibition of CB2, either by gene silencing or by small molecule inhibitors, 
results in an increased sensitivity to bleomycin induced dermal fibrosis. 
 To evaluate, whether activation of CB2 exerts anti-fibrotic effects, CB2 +/+ mice were 
treated with the selective CB2 agonist JWH-133 in pharmacologically relevant 
concentrations, while challenged with bleomycin. Treatment with JWH-133 ameliorated the 
pro-fibrotic effects of bleomycin and significantly reduced the dermal thickening by 35 ± 3 % 
(p = 0.004) (Figures 3 and 4). Thus, activation of CB2 signaling exerts anti-fibrotic effects in 
vivo. 
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CB2 regulates the infiltration of leukocytes into lesional skin  
 Accumulation of leukocytes into lesional skin is characteristic for the mouse model of 
bleomycin induced dermal fibrosis and of early stages of SSc. To analyze, whether CB2 
affects leukocyte infiltration in experimental fibrosis, the numbers of leukocytes in lesional 
skin were quantified. The numbers of infiltrating leukocytes were significantly increased in 
CB2 -/- mice compared to CB2 +/+ mice (Figure 1). 38.2 ± 3.1 leukocytes per high power field 
were detected in sections from lesional skin of CB2 -/- mice compared to 27.7 ± 3.5 in CB2 +/+ 
mice (p = 0.016). Consistent with these results, greater numbers of leukocytes were also 
detected in CB2 +/+ mice upon treatment with the CB2 antagonist AM-630 (37.1 ± 1.6, p = 
0.047). On the other hand, the infiltration of leukocytes into lesional skin was strongly 
reduced in CB2 +/+ mice treated with the CB2 agonist JWH-133 to 17.7 ± 1.4 (p = 0.009).   
 
The phenotype of CB2 -/- mice is mediated by bone marrow derived cells 
To investigate, whether the increased susceptibility of CB2 -/- mice to fibrosis is based 
on lack of CB2 on bone marrow derived cells or on fibroblasts and other mesenchymal cells, 
bone marrow transplantation experiments were performed and the resulting chimeric mice 
were challenged with bleomycin. Transplantation of CB2 -/- mice with bone marrow from 
CB2 +/+ mice and subsequent challenge with bleomycin resulted in comparable increases in 
dermal thickness as in CB2 +/+ mice with CB2 +/+ bone marrow with increases of 45 ± 6 % and 
53 ± 3 %, respectively, as compared to NaCl treated mice (Figures 5 and 6). In contrast, 
transplantation of CB2 +/+ mice with bone marrow cells from CB2 -/- mice fully resembled the 
phenotype of CB2 -/- mice. Challenge of CB2 +/+ mice reconstituted with bone marrow from 
CB2 -/- mice resulted in a 77 ± 7 % increase in dermal thickness. This increase was 
significantly higher than in CB2 +/+ mice with CB2 +/+ bone marrow (p = 0.03), but did not 
differ from the increase observed in CB2 -/- mice (p = 0.67) (Figures 5 and 6). Together, these 
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data demonstrate that CB2 deficiency on bone marrow derived cells mediates the increased 
susceptibility of CB2 -/- mice to experimental fibrosis. 
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Discussion 
 In the present study, we demonstrate that CB2 exerts anti-fibrotic effects in vivo. 
Inhibition of CB2 signaling by either gene silencing or treatment with small molecule 
inhibitors increased the susceptibility to bleomycin induced dermal fibrosis. Accumulation of 
thickened collagen fibers and dermal thickening upon challenge with bleomycin were more 
pronounced in CB2 -/- mice as well as in mice treated with the CB2 antagonist AM-630. On 
the other hand, activation of CB2 signaling by the selective agonist JWH-133 prevented the 
pro-fibrotic effects of bleomycin and significantly reduced the dermal thickening at 
pharmacologically relevant doses. Consistent with our results, anti-fibrotic effects of CB2 
were also observed in the liver and pancreas (7, 14). Based on these preclinical data, 
activation of CB2 by selective agonists might be a novel approach for the treatment of 
fibrosis. In SSc, this approach might be particular promising for patients in early 
inflammatory stages of the disease. Of note, CB2 agonists are currently evaluated in clinical 
trials for multiple sclerosis (5, 6). In these clinical trials, CB2 agonists were well tolerated. 
Major adverse events such as dizziness, drowsiness or headache were due to incomplete 
selectivity of these first compounds with co-activation of the CB1 receptor. Thus, our study 
could have direct clinical impact since CB2 agonists are well tolerated and already available 
for clinical trials in patients with fibrotic disorders such as SSc. 
We show in vivo that CB2 mediates its anti-fibrotic effects by inhibiting the 
infiltration of leukocytes into lesional skin in preclinical models of SSc. Inhibition of CB2 
signaling by either genetical knockout or the chemical inhibitor AM-630 increased the 
accumulation of leukocytes at bleomycin injected skin areas. Consistent with our findings in 
experimental fibrosis, exacerbation of inflammation in mice deficient for CB1 and CB2 (CB1 
-/- CB2 -/-) was observed in experimental contact dermatitis (9). Infiltration of leukocytes into 
lesional skin is a common feature in early stages of SSc and in the mouse model of bleomycin 
induced dermal fibrosis. The infiltrating leukocytes activate the collagen synthesis of resident 
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fibroblasts by the release of pro-fibrotic mediator. Thus, CB2 signaling might affect the 
outcome of fibrosis indirectly by orchestrating the infiltration of leukocytes into lesional skin 
rather than by direct effects on the collagen synthesis of fibroblasts. Consistent with this 
hypothesis, the increased susceptibility of CB2 -/- mice to experimental fibrosis was fully 
resembled by transplantation of CB2 deficient bone marrow cells into CB2 +/+ mice. In 
contrast, the phenotype of CB2 -/- mice transplanted with CB2 +/+ bone marrow did not differ 
from that of CB2 +/+ mice with CB2 +/+ bone marrow, arguing against a direct effect of CB2 
signaling on fibroblasts. This hypothesis was further supported by studies on cultured 
fibroblasts. Neither activation nor inhibition of CB2 altered the release of collagen or other 
major extracellular matrix proteins in cultured fibroblasts from SSc patients or healthy 
individuals (data not shown). Therefore, we propose that activation of CB2 inhibits leukocyte 
activation and migration into lesional skin in fibrotic diseases. The reduced infiltration of 
leukocytes and the decreased release of pro-fibrotic mediators subsequently results in a less 
pronounced stimulation of resident fibroblasts and protection from fibrosis.  
On the molecular level, CB2 might exert its effects by regulating the expression of 
chemokines and affecting chemotaxis of leukocytes (6, 15). In particular, regulation of the 
expression of MCP-1 (CCL2) and its receptor CCR2 might be important for fibrotic diseases. 
MCP-1 exerts potent chemotactic effects on inflammatory cells via activation of CCR2. MCP-
1 is upregulated in the skin of SSc patients and has been implicated in the pathogenesis of the 
disease (16). MCP-1 might contribute to the development of fibrosis either by direct effects 
on fibroblasts or indirectly by stimulating the release of interleukin-4 from T cells (17, 18). 
Activation of CB2 reduced the expression of MCP-1 and its receptor CCR2 in myeloid 
progenitor cells, whereas inhibition of CB2 stimulated their expression (15).  
The mouse model of bleomycin induced dermal fibrosis has limitations. The effect of 
bleomycin is not irreversible in this model and dermal fibrosis spontaneously resolves over 
time. However, we demonstrated recently that dermal thickening during challenge with 
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bleomycin progresses during the first six weeks and that the fibrotic changes persist for at 
least 3 weeks after the last bleomycin injection (19). Thus, we performed our analyzes in a 
dynamic phase of progressive dermal fibrosis. Another limitation of the mouse model of 
bleomycin induced dermal fibrosis is that this model mimics early, inflammatory stages of 
SSc, but is less suitable for later stages of SSc, where inflammatory infiltrates are rarely 
observed. Therefore, our findings in the mouse model of bleomycin induced fibrosis implicate 
a potential role of CB2 in early stages of SSc, but the results should not be extrapolated to 
later stages of SSc. Moreover, additional studies are necessary to investigate the role of CB2 
for the development of fibrosis in other organ systems such as the lung.  
In summary, we demonstrate that CB2 exerts anti-fibrotic effects by limiting leukocyte 
infiltration and subsequent fibroblast activation in lesional skin. These data suggest that 
activation of CB2 might be a promising approach for therapy of early inflammatory stages of 
SSc. Since CB2 agonists are available and seem to be well tolerated, these findings might 
stimulate first clinical trials in patients with SSc and other fibrotic diseases. 
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Figure legends 
Figure 1: Increased dermal thickness in CB2 -/- mice upon challenge with bleomycin. No 
differences in dermal thickness were observed between CB2 -/- mice and CB2 +/+ mice 
injected with NaCl. However, challenge with bleomycin resulted in a significantly greater 
dermal thickening in CB2 -/- mice injected than in CB2 +/+ mice. Representative sections at 
100-fold magnification.  
 
Figure 2: CB2 -/- mice are more sensitive to dermal fibrosis upon challenge with bleomycin. 
Mean dermal thickness expressed as x-fold increases compared to CB2 +/+ mice injected with 
NaCl. n = 8 for each group. 
 
Figure 3:  Treatment with the CB2 antagonist AM-630 increases the sensitivity to bleomycin 
induced fibrosis, whereas the selective CB2 agonist JWH-133 ameliorates experimental 
fibrosis. Treatment of CB2 +/+ mice with AM-630 significantly increased dermal thickness 
upon challenge with bleomycin and resembled the phenotype of CB2 -/- mice. In contrast, 
treatment with the selective CB2 agonist JWH-133 prevented the pro-fibrotic effects of 
bleomycin. Representative sections of lesional skin at 100-fold magnification.  
 
Figure 4: Pharmacologic inhibition of CB2 by AM-630 exacerbates bleomycin induced 
fibrosis, whereas activation of CB2 by JHW-133 reduces dermal thickening. Mean dermal 
thickness expressed as x-fold changes compared to mice injected with NaCl. n = 6 for each 
group. 
 
Figure 5: The increased susceptibility of CB2 -/- mice to experimental fibrosis is mediated by 
bone marrow derived cells. CB2 -/- mice were transplanted with bone marrow from CB2 +/+ 
mice after lethal irradiation and vice versa and subsequently challenged with bleomycin. The 
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dermal thickening in these chimeric mice was compared to that of CB2 +/+ mice with CB2 +/+ 
bone marrow and CB2 -/- mice with CB2 -/- bone marrow. The phenotype of CB2 -/- mice was 
completely mimicked by transplantation of CB2 -/- bone marrow into CB2 +/+ mice, whereas 
CB2 -/- mice reconstituted with CB2 +/+ bone marrow did not display increased sensitivity to 
fibrosis. Representative sections at 100-fold magnification.  
 
Figure 6: Bone marrow transplantation experiments reveal that the increased sensitivity of 
CB2 -/- to bleomycin induced fibrosis is mediated by bone marrow derived cells. Mean dermal 
thickness expressed as percent increases compared to CB2 +/+ mice with CB2 +/+ bone marrow 
injected with NaCl. n = 6 for each group. 
 
